MT
Matinas BioPharma Holdings, Inc.
MTNB · AMEX
$0.16 -15.83% (-$0.03)
1M -27.99%
Market Cap $1.04M
P/E Ratio -
Div. Yield -
ROE 181.46%
Bulios Fair Price
$0.19
17.6% upside
Current Price
$0.16
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MTNB is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.58x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining Book val. growth 49.10%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 323.22%
Asset turnover 0.00x
ROE 181.46%
Debt
76 /100
Low Debt/Equity 0.00x
Current ratio 0.85x
Int. coverage N/A
Stability
13 /100
Unstable Beta 1.70x
Profitable years 0
EPS volatility 68.38%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MTNB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jerome D. Jabbour
Employees
2
Headquarters
Bedminster
Upcoming events
12 NOV
Earnings
Upcoming earnings report